BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

[1]  M. Tsao,et al.  Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population‐based reflex testing , 2019, Cancer.

[2]  S. Toyooka,et al.  Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  D. Planchard,et al.  Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer , 2019, Clinical Cancer Research.

[4]  Sarah H. Johnson,et al.  Identification and Development of a Lung Adenocarcinoma PDX Model With STRN‐ALK Fusion , 2019, Clinical lung cancer.

[5]  A. Shaw,et al.  Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.

[6]  M. Tiemann,et al.  Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Jae Woo Choi,et al.  Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. , 2018, Lung cancer.

[8]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[9]  Young Hak Kim,et al.  Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model , 2018, Molecular Cancer Research.

[10]  Markus Riester,et al.  Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. , 2018, JCO precision oncology.

[11]  S. Digumarthy,et al.  Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study. , 2018 .

[12]  M. Lawrence,et al.  Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. , 2018, Cancer discovery.

[13]  H. Nehoff,et al.  ALK and IGF-1R as independent targets in crizotinib resistant lung cancer , 2017, Scientific Reports.

[14]  S. Ou,et al.  Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. , 2017, Lung cancer.

[15]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[16]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[17]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[18]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[19]  I. Jurisica,et al.  Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[21]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[22]  A. Iafrate,et al.  Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib , 2014, Clinical Cancer Research.

[23]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[24]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[25]  J. Christensen,et al.  HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[27]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[28]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[29]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.